Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lanfang Li
Observed name:
L. Li
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Pudong Medical Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Tianjin Medical University Cancer Institute and Hospital,
Pudong Medical Center,
Affiliated Hospital of Jining Medical University,
Jining Medical University,
Tianjin Medical University
show all 7
ORCID:
0009-0009-4088-4430
Observed ORCID:
0009-0009-4088-4430
OpenAlex ID:
A5049687339
CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma
2024
·
Xiyue Xu
, Yidan Zhang
, et al.
·
Cancer Research
·
36
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B‐Cell Lymphoma: A Real‐World, Multi‐Center, Retrospective Cohort Study
2024
·
Peiqi Zhao
, Shu Zhao
, et al.
·
Hematological Oncology
·
24
Akkermansia muciniphila reduces neuroinflammation and Aβ deposition via tryptophan metabolism in the APP/PS1 mouse model of Alzheimer’s disease
2026
·
Binghua Wang
, Miaomiao Pan
, et al.
·
Alzheimer s Research & Therapy
·
22
Differential expression pattern of CC chemokine receptor 7 guides precision treatment of hepatocellular carcinoma
2025
·
Jie Qin
, Qianyi Gong
, et al.
·
Signal Transduction and Targeted Therapy
·
16
PDF
Single-cell and bulk transcriptomics reveal a CD8+ T-cell gene signature predicting prognosis in diffuse large B-cell lymphoma
2025
·
Hengqi Liu
, Yingfang Feng
, et al.
·
Frontiers in Immunology
·
4
PDF
A nomogram for predicting the risk of tigecycline-associated drug-induced liver injury in a Chinese population
2025
·
Xin Zhang
, Lanfang Li
, et al.
·
Scientific Reports
·
4
PDF
Clinical Features and Outcomes of Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified, Treated with CHOP-Based Regimens
2025
·
Ge Hu
, Zheng Song
, et al.
·
Cancers
·
4
PDF
Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
2025
·
Fenghua Gao
, Cong Sun
, et al.
·
Hematological Oncology
·
2
Enhancer of Zeste Homolog 2 (ezh2) Inhibitor Shr2554 in Relapsed or Refractory (r/r) Peripheral T‐cell Lymphoma (ptcl): Updated Outcomes From the First‐in‐human Phase 1 Study
2023
·
Y. Song
, J. Zhu
, et al.
·
Hematological Oncology
·
2
PDF
61 | a Pivotal Study of Shr2554, an Oral Inhibitor Against Enhancer of Zeste Homolog 2 (ezh2), in Relapsed or Refractory (r/r) Peripheral T‐cell Lymphoma (ptcl)
2025
·
Y. Song
, Z. Li
, et al.
·
Hematological Oncology
·
1
PDF
48 | Novel Triplet Combination of Orelabrutinib, Lenalidomide, and Rituximab as Frontline Therapy for Mantle Cell Lymphoma: Final Results of Polaris Multicenter Phase Ii Study
2025
·
H. Zhang
, L. Su
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Sequential Chemotherapy/radiotherapy Was Superior to Sandwich Therapy for Primary Early‐stage Dlbcl of Waldeyer's Ring
2019
·
X. Wang
, Q. Zhou
, et al.
·
Hematological Oncology
·
1
An intact tumor microenvironment in patient-derived NSCLC organoids facilitates subtype-specific drug profiling
2026
·
Zihao Chen
, Hongdou Ding
, et al.
·
Research Square
Clinical activity and immune correlates of glofitamab combined with tislelizumab in relapsed/refractory follicular lymphoma: A translational study
2025
·
Zhao Peiqi
, Lanfang Li
, et al.
·
Blood
ZAP trial: MRD-guided chemotherapy and maintenance de-escalation with zanubrutinib-g-CHOP in high-risk FL (Phase II)
2025
·
Zhao Peiqi
, Lanfang Li
, et al.
·
Blood
1243MO Risk stratification for diffuse large B-cell lymphoma by integrating interim 18F-FDG PET-CT analysis and the NCCN-IPI: A multicentre retrospective study
2025
·
J. Wang
, Y. Sun
, et al.
·
Annals of Oncology
642 | Real‐world Efficacy and Safety of Glofitamab in Chinese Patients With R/r Dlbcl: High Response Rates in High‐risk Populations
2025
·
Z. Qian
, L. Li
, et al.
·
Hematological Oncology
PDF
516 | Risk Stratification for Diffuse Large B‐cell Lymphoma by Integrating Interim 18f‐fdg Pet‐ct Analysis and the Nccn‐ipi: a Multicentre Retrospective Study
2025
·
J. Wang
, Y. Sun
, et al.
·
Hematological Oncology
PDF
484 | Single‐cell Analysis of Circulating Immune Heterogeneity in Diffuse Large B‐cell Lymphoma Highlights Distinct Immune Cell Signatures in Immunotherapy
2025
·
S. Zhang
, X. Meng
, et al.
·
Hematological Oncology
PDF
490 | Molecular Landscape of Distinct Follicular Lymphoma Histologic Grades: Insights From Genomic and Transcriptome Analyses
2025
·
C. Sun
, H. Liu
, et al.
·
Hematological Oncology
PDF
474 | Cd73 Modulates Immune Escape Via Tryptophan Metabolic Reprogramming in Diffuse Large B‐cell Lymphoma
2025
·
Y. Feng
, N. Zhang
, et al.
·
Hematological Oncology
PDF
Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study
2024
·
Zhao Peiqi
, Shu Zhao
, et al.
·
Blood
PDF
Data from CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma
2024
·
Xiyue Xu
, Yidan Zhang
, et al.
Data from CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma
2024
·
Xiyue Xu
, Yidan Zhang
, et al.
Supplementary Data from CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma
2024
·
Xiyue Xu
, Yidan Zhang
, et al.
Show more works
View as search
Works count:
38
Citation count:
117
H-index:
4
I10-index:
4
Year
Topic
Type